KLF13 promotes SLE pathogenesis by modifying chromatin accessibility of key proinflammatory cytokine genes
Andrew Wang,Anna-Marie Fairhurst,Kui Liu,Benjamin Wakeland,Spencer Barnes,Venkat S. Malladi,Kasthuribai Viswanathan,Carlos Arana,Igor Dozmorov,Amrita Singhar,Yong Du,Marjaan Imam,Angela Moses,Christian Chen,Ashwini Sunkavalli,Jose Casco,Dinesh Rakheja,Quan-Zhen Li,Chandra Mohan,Carol Clayberger,Edward K. Wakeland,Shaheen Khan
DOI: https://doi.org/10.1038/s42003-024-07099-0
IF: 6.548
2024-11-07
Communications Biology
Abstract:Although significant progress has been achieved in elucidating the genetic architecture of systemic lupus erythematosus (SLE), identifying genes underlying the pathogenesis has been challenging. The NZM2410-derived lupus susceptibility Sle3 locus is associated with T cell hyperactivity and activated myeloid cells. However, candidate genes associated with these phenotypes have not been identified. Here, we narrow the Sle3 locus to a smaller genomic segment ( Sle3k ) and show that mice carrying Sle3k and Sle1 loci developed lupus nephritis. We identify Klf13 as the primary candidate gene that is associated with genome-wide transcription changes resulting in higher levels of proinflammatory cytokines, enhanced T cell activation, and hyperresponsiveness of myeloid cells. Correspondingly, Klf13 –/– mice display repression of genes involved in mediating immune activation, including key proinflammatory cytokines/chemokines in T cells and dysregulation in cytokine signaling pathways in myeloid cells in response to toll receptor ligands. Klf13 upregulation is associated with increased production of RANTES, a key chemokine in lupus nephritis, in activated T cells and the kidneys of lupus-prone mice. In sum, our findings reveal Klf13 as a key gene in the Sle3 interval in mediating lupus pathogenesis that may have implications in the rational design of new therapies for SLE.
biology